References

Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study

10.1200/jco.21.00931 · 2022 · External reference

Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM-2

10.1182/blood-2022-158406 · 2022 · External reference

Relapse is uncommon in patients with large B-cell lymphoma who are in complete remission at the end of fixed-course glofitamab treatment

10.1182/blood-2022-157554 · 2022 · External reference

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

10.1016/s0140-6736(21)00889-8 · 2021 · External reference

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma

10.1056/nejmoa2206913 · 2022 · External reference

Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial

10.1200/jco.22.01725 · 2023 · External reference

Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial

10.1200/jco.20.03175 · 2021 · External reference

CAR T-cell therapy for B-cell lymphoma

10.1016/j.currproblcancer.2021.100826 · 2022 · External reference

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

10.1038/s41591-020-1061-7 · 2020 · External reference

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma

10.1182/bloodadvances.2021005954 · 2022 · External reference

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

10.1200/jco.2013.54.8800 · 2014 · External reference

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

10.1182/blood.2023022348 · 2024 · External reference

Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy

10.1182/blood.2023021672 · 2024 · External reference

Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2

10.1200/jco.2023.41.16_suppl.tps7592 · 2023 · External reference

Characterization of JNJ-80948543, a novel CD79bxCD20xCD3 trispecific T-cell redirecting antibody for the treatment of B-cell non-Hodgkin lymphoma

10.1182/blood-2022-168739 · 2022 · External reference

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

10.1182/blood.2022015956 · 2022 · External reference